Mast Therapeutics is focused on developing therapies for patients with serious and life-threatening diseases. The biopharmaceutical company’s lead product candidate, MST-188, is designed to treat patients with sickle cell disease. The hemorheologic, cytoprotective and anti-inflammatory therapy is currently in phase 3 trials. Headquartered in San Diego, California, the company used to operate as ADVENTRX Pharmaceuticals. For more information, please visit the company’s website at www.masttherapeutics.com.